Trials / Completed
CompletedNCT04139824
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
A Phase 1, Open-label, Fixed-sequence, 2-way Drug Interaction Study to Evaluate the Effect of Naproxen on the Pharmacokinetics of LC350189 and the Effect of LC350189 on the Pharmacokinetics of Naproxen in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in combination in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xanthine Oxidase Inhibitor | LC350189 200mg qd |
| DRUG | nonsteroidal anti-inflammatory drug | Naproxen 500mg BID |
Timeline
- Start date
- 2020-01-22
- Primary completion
- 2020-02-25
- Completion
- 2020-02-25
- First posted
- 2019-10-25
- Last updated
- 2020-06-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04139824. Inclusion in this directory is not an endorsement.